View
11
Download
0
Category
Preview:
Citation preview
Dream – Visualize - Lead
PUBLIC EXPOSE
PT DARYA-VARIA LABORATORIA TbkFairmont Hotel, Jakarta, June 11, 2019
Dream – Visualize - Lead
Topik / Topics :
1. Tinjauan PasarMarket Overview
2. Sekilas tentang DVLDVL at a Glance
3. Tinjauan Bisnis DVL Tahun 2018DVL Business Overview FY 2018
4. Kinerja DVL Kuartal 1-2019 DVL Performance 1st Q-2019
Kondisi UmumGeneral ConditionsKondisi Umum
General Conditions
Ekonomi Indonesia di 2018 tumbuh lebih tinggi dari tahun sebelumnya,dengan nilai inflasi yang terkendali
Indonesian economy in FY 2018 is growing faster than last year, with inflation rate controlled
GPD Growth ( % ) Inflation MAT ( % )
SOURCE: BPS.GO.ID
Kondisi UmumGeneral Conditions
SOURCE: NIELSEN CPS DATA – ADDITIONAL SPENDING +79 FMCG HOMEPANEL – MAT Q4 2017 VS MAT Q4 2018
% GROWTH (SPEND/BUYER)
Secara umum, rumah tangga mempertahankan pengeluaran rutinnya.RT masih mau menambah pengeluaran untuk bersenang-senang dan pemeliharaan
rumah, namun mengurangi pengeluaran untuk kesehatan dan pendidikanIn general, household are maintaining their regular spending.
However HH are still willing to increase Leisure & Housing Related but at the same time they reduce spending in Health & Education.
Kondisi UmumGeneral Conditions
SOURCE: (1) BPS OFFICIAL GOVERNMENT SITE, & NIELSEN RETAIL DATA
Trend FMCG masih terus melambat ; kategori kebutuhan tertier masih bertumbuh, sementara kategori kebutuhan sehari-hari masih belum membaik
The slowing down trend of FMCG industry is still continue; indulgence categories are growing, while daily usage categories are suffering
TOP 20 CATEGORY – VALUE GROWTHFMCG – VALUE & VOLUME GROWTH
Kondisi UmumGeneral ConditionsKondisi Umum
General Conditions
Pasar farmasi Indonesia mengalami pertumbuhan 2% pada MAT Q3 2018;Pasar OTC menurun hampir 9% (IQVIA Combined Audit 3Q 2018).
Indonesian pharmaceutical market has increased to 2.0% in MAT Q3 2018The OTC market largely declined by nearly 9% (IQVIA Combined Audit 3Q 2018).
Source : Combined Audit 3Q18 2 (Combined Audit : Hospital + Pharmacy + Drugstore)
“Menteri Keuangan Sri Mulyani menyebut hasil audit BPKP menunjukkan defisit keuangan pada BPJS Kesehatan tahun lalu mencapai Rp 9,1 triliun. ”
“Ministry of Finance Sri Mulyani mention result of BPKP audit shown last year BPJS Kesehatan budget deficit reach Rp. 9.1 T.” [CNN Indonesia | Selasa, 28/05/2019)
Source: BPJS.go.id
Jaminan Kesehatan NasionalNational Health Insurance
Q1-2019
221mio
(84% coverage)
2018
208mio
2017
188mio
2016
172mio
2015
157mio
2014133mio
SEKILASTENTANG DVL
DVL AT A GL ANCE
1976
FEBRUARI/FEBRUARYPerseroan didirikan
The company established
1994
OKTOBER/OCTOBERPenawaran Umum Perdana
sebanyak sepuluh juta saham
Initial Public Offeringof ten million shares
2001
DESEMBER/DECEMBERFar East Drug (BVI) Co. Ltd.
membeli 17.716.940 saham perseroan
Far East Drug (BVI) Co. Ltd. purchased 17,716,940 shares of the Company
2005
Pabrik Gunung Putri dan Citeureup keduanyamendapatkan sertifikasi GMP strata-A
Both Gunung Putri and Citeureup Plant facilities received strata-A GMP certification
2012
Membukukan Rp 1 Trillion dari total penjualanbisnis Ethical, OTC dan Toll & Export
Registered IDR 1 Trillion combined sales from Ethical, OTC and Toll & Export business
2018
DESEMBER/DECEMBERPenghargaan Halal 2018
untuk Natur-E oleh LPPOM-MUI
Halal Award 2018 for Natur-E given by LPOM-MUI
Bisnis Obat ResepPrescription Business
Bisnis Consumer HealthConsumer Health Business
Bisnis Ekspor& Jasa Toll Manufacturing
Export & Toll Manufacturing Business
Segmen Bisnis UtamaMain Business Segments
Fasilitas ProduksiProduction Facilities
Citeureup, BogorProduk Steril & Padat
Sterile & Solid
Gunung Putri, BogorKapsul Lunak, Cairan, KosmetikSoft Capsule, Liquid, Cosmetic
IKHTISARDVL
DVL HIGHLIGHTS
Peluncuran Produk BaruNew Products Launch
MAY 2018: Natur-E Advanced Face Series
MAR 2018: Orvast dan Atorvastatain NOV 2018: Epifri
SEP 2018: Nomatic dan Pregabalin
Kegiatan PemasaranMarketing Activities
Medical Congress
Scientific Seminars TVC
On the ground Activities
TINJAUAN BISNISDVL TAHUN 2018
D V L B U S I N E S S O V E R V I E W
F Y 2 0 1 8
Kinerja DVL Tahun 2018DVL Performance FY 2018
Bisnis Obat Resep(Prescription Business)
Bisnis Obat Bebas(Consumer Health Business)
Bisnis Export & Jasa Toll Manufacturing(Export & Toll Manufacturing Business)
580 M 705 M 415 M
8 %
TOTALPertumbuhan
Growth
8%
1.700 MPenjualan Bersih
Net Sales
-5.5 % 41.7%
2017 2018
894 925
LAPORAN LABA RUGI STATEMENT OF PROFIT OR LOSS
2017 2018
220 267
2017 2018
162 201
Marjin Laba BersihNet Income Margin
201710,3%
201811,8%
Laba BrutoGross Income
Laba UsahaOperating Income
Laba BersihNet Income
2017 2018
Laba Bersih per Saham(Rupiah Penuh)
Net Income per Share(Full Rupiah)
145 180
(dalam miliar Rupiah)(in billion Rupiah)
3.5% 21.5% 23.7% 24%% Pertumbuhan% Growth
2017 2018
1.641 1.683
2017 2018
1.176 1.203
2017 2018
525 483
Total AsetTotal Assets
Aset LancarCurrent Assets
Total LiabilitasTotal Liabilities
2017 2018
EkuitasEquity
1.116 1.200
(dalam miliar Rupiah)(in billion Rupiah)
2.6% 2% -8% 7,5%% Pertumbuhan% Growth
LAPORAN POSISI KEUANGAN STATEMENT OF FINANCIAL POSITION
Arus kas dari operasionalCash flows from operations
2018
2017
Decrease: 88,5%
Arus kas untuk aktivitas investasiCash flows used in investing activities
2018
2017
Increase: 43%
Arus kas untuk aktivitas pendanaanCash flows used in financing activities
2018
2017
Increase: 7%
LAPORAN ARUS KASSTATEMENT OF CASH FLOWS
DVL PERFORMANCE
1 s t Q - 2019
KINERJA DVLKUARTAL 1-2019
Kinerja Kuartal 1-2019Q1 2019 Performance
I. Total Penjualan Bersih DVL sebesar Rp 482 miliar- DVL tumbuh sebesar 12%
II. Apa yang mendukung kinerja bisnis?- Pertumbuhan Ekspor dan Jasa Toll
Manufacturing
III. Tantangan bisnis- Bisnis obat resep- Bisnis obat bebas
I. Total DVL Net Sales at Rp 482 bio- DVL grew by 12%
II. What drove the business?
- Export and Toll Manufacturing growth
III. Business challenges
- Prescription drugs
- Consumer Health
IV. Keuangan :
- Laba Bruto, Laba Usaha & Laba Bersih DVL
tetap terjaga
IV. Financials :
- DVL Gross Income, Operating Income &
Net Profit are on track
V. Program Sampai Dengan Akhir Tahun yang
terencanaV. Balance Year Program in place
SESITANYA JAWAB
Q U E S T I O N S A N D A N S W E R S
DVL PUBL IC EXPOSE
Recommended